ABOUT MiNA
Harnessing the innate mechanism of gene activation, MiNA Therapeutics’ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases.
PIONEERING NEW CLASS OF MEDICINES
Small activating RNAs are an entirely new class of medicines with potential to offer transformational benefits to patients across a wide range of diseases.
CLINICAL STAGE PLATFORM
We have developed a systematic approach to take new saRNA medicines from an idea to patients in a clinical trial in just 2 years.
EXPERIENCED TEAM
Driving our platform are a group of passionate scientists, drug developers, doctors and entrepreneurs shaped by experience in oligonucleotide therapeutics, cancer and liver diseases.
TWITTER FEED
Follow us on Twitter
Grateful to be featured by .@Labiotech_eu in their roundup of London’s Top 10 Biotechs
These are the 10 #biotechs in #London you don't want to miss out! 🤓 @ReViral_ltd @CellMedica @AutifonyLtd @VirionBio
https://t.co/v8JjNhVd3V
Kicking off summer with mini-golf fun and valete to David who leaves as top points scorer
In depth discussion with our CEO .@robertshabib and @WuXi_AppTec on saRNA medicines and the coming wave of RNA therapeutics broadly.
WuXi AppTec on Twitter
”CEO of MiNA Therapeutics, Robert Habib, discusses how they are pioneering a new class of medicines called #saRNAs (small activating RNAs) that ...
twitter.com
CEO of MiNA Therapeutics, Robert Habib, discusses how they are pioneering a new class of medicines called #saRNAs (small activating RNAs) that can upregulate intracellular or secreted proteins for therapeutic benefit #InnovationThatMatters
Read more: https://t.co/kq8axAslVB
Congratulations to John Rossi @cityofhope recipient of the 2019 Outstanding Achievement Award, American Society of Gene & Cell Therapy! @ASGCTherapy
Also looking forward to back-to-back presentations on MTL-CEBPA saRNA drug candidate today 4-430pm in Heights Courtyard 1 #ASGCT19